Zaccardi F, et al. - Researchers, using data from randomised controlled trials (RCTs), evaluated differences among statins with respect to benefits on the risk of venous thromboembolism (VTE). They also examined the link between risk of VTE and reduction of low-density-lipoprotein-cholesterol (LDL-c) levels. A partial association of reduced VTE risk with LDL-c reduction was demonstrated in RCTs with statin treatment. Also, data showed that the benefit was larger than that observed for atherothrombotic risk. Network meta-analysis indicated a larger benefit for rosuvastatin compared to placebo and other statins.